JPMorgan initiated coverage of Neurogene with an overweight rating and a price target of $60, implying 132% upside from Wednesday’s close. The stock has fallen approximately 32% over the past three months, hit by a broader pullback in biotech stocks and weaker-than-expected second-quarter financial results. The bank is betting on NGN-401, an experimental gene therapy for Rett syndrome, with new trial data expected in 2027. According to LSEG data, all ten analysts covering the stock have a buy or strong buy rating on shares.
Source: Read the original article
Disclaimer: this content is for information purposes only and is not financial advice. Cryptocurrencies are highly volatile: you may lose all of your capital. Always do your own research. Legal notice
